Perceptions of patients with inflammatory bowel diseases on switching from reference product adalimumab to biosimilar adalimumab-atto
There was widespread satisfaction with adalimumab-atto after switching from RP adalimumab. Nevertheless, participants reported limited knowledge of adalimumab-atto, suggesting a need for enhanced education on biosimilars.
Authors
- Rita L. Hui (ORCID: https://orcid.org/0000-0003-0014-2431)
- Kim Ngoc Le
- Fang Niu (ORCID: https://orcid.org/0009-0004-3439-7410)
- Catherine Pham (ORCID: https://orcid.org/0009-0001-8156-374X)
- Thomas Delate (ORCID: https://orcid.org/0000-0002-6530-8415)
- Dounia Bitar
Institutions
- Kaiser Permanente (US)
Publication Details
- Journal
- Expert Opinion on Biological Therapy
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1080/14712598.2025.2488222
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00